Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 01, 2015 5:24 PM ET

Life Sciences Tools and Services

Company Overview of Quintiles Transnational Corp.

Company Overview

Quintiles Transnational Corp. provides contract research, clinical trial, and pharmaceutical consulting services to biopharmaceutical and other life science companies in the United States and internationally. It offers clinical trial execution services in the areas of clinical biostatistics, clinical data management, clinical development, phase I/IIa, phase II/III, clinical monitoring, cardiac safety ECG monitoring, late phase, patient recruitment, project management, regulatory affair, risk-based monitoring, safety and pharmacovigilance, and site start-up aspects; and consulting services, such as change management, market intelligence, process and information technology implementation, prod...

4820 Emperor Boulevard

Durham, NC 27703-8411

United States

Founded in 1990

Phone:

919-998-2000

Fax:

919-998-2003

Key Executives for Quintiles Transnational Corp.

Chief Executive Officer and Director
Age: 56
Executive Chairman and Member of Executive Committee
Age: 71
Chief Financial Officer
Age: 52
Chief Executive Officer of AAA Region and President of AAA Region
Age: 66
Chief Executive Officer of Africa
Compensation as of Fiscal Year 2015.

Quintiles Transnational Corp. Key Developments

Quintiles Transnational Corp. Announces Pricing of $800 Million Senior Notes Offering

Quintiles Transnational Holdings Inc. announced that Quintiles Transnational Corp., its subsidiary, has priced $800 million principal amount of 4.875% senior unsecured notes due 2023 offered in a private placement that is exempt from the registration requirements of the Securities Act of 1933, as amended. The company intends to use the net proceeds of the offering, together with proceeds from its previously announced proposed senior secured credit facility, which is expected to increase to a total of $1.95 billion, including $1.45 billion of term loans, to refinance its existing credit facility, as well as for general corporate purposes, including corporate transactions and equity repurchases. The Senior Notes will be fully and unconditionally guaranteed on an unsecured basis by Quintiles Transnational’s domestic subsidiaries that guarantee the senior secured credit facility. The issuance of the Senior Notes is expected to occur on or about May 12, 2015, concurrently with the expected closing of the new senior secured credit facility, subject to customary closing conditions. The Senior Notes are being offered in the United States only to qualified institutional buyers pursuant to Rule 144A under the Securities Act and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.

Quintiles Transnational Corp. Announces Proposed Offering of $800 Million of Senior Notes

Quintiles Transnational Corp. announced a $800 million principal amount of senior unsecured notes due 2023 (the Senior Notes"), subject to market and other conditions. The Senior Notes will be offered in a private placement that is exempt from the registration requirements of the Securities Act of 1933, as amended (the Securities Act"). The company intends to use the net proceeds of the offering, together with proceeds from its previously announced proposed new senior secured credit facility, to refinance its existing credit facilities, as well as for general corporate purposes, including corporate transactions and equity repurchases. The Senior Notes will be fully and unconditionally guaranteed on an unsecured basis by certain of Quintiles Transnational's domestic subsidiaries. The Senior Notes will be offered in the United States only to qualified institutional buyers pursuant to Rule 144A under the Securities Act and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.

Quintiles Transnational Corp. Presents at CED Life Science Conference 2015, Mar-03-2015 through Mar-04-2015

Quintiles Transnational Corp. Presents at CED Life Science Conference 2015, Mar-03-2015 through Mar-04-2015. Venue: Raleigh Convention Center, Raleigh, North Carolina, United States. Presentation Date & Speakers: Mar-03-2015, Thomas H. Pike, Chief Executive Officer. Mar-04-2015, Dennis B. Gillings, Executive Chairman and Member of Executive Committee.

Similar Private Companies By Industry

Company Name Region
Prime Credit Corp United States
Almac Clinical Services Inc. United States
Blaze Bioscience, Inc. United States
Cognigen Corporation United States
Charles River Laboratories, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Quintiles Transnational Corp., please visit www.quintiles.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.